GlassScriptPhysician profile
Miriam L Ibrahim
NPI 1194768549
$2,230.66
in general payments reported to CMS, 2019-2025
27 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $1,269 · 2021: $217 · 2022: $102 · 2023: $123 · 2024: $37.74 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $391.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,266.16 | 2019-2020 | |
| Biogen, INC. | $124.74 | 2021 | |
| Lilly USA, LLC | $111.63 | 2019-2023 | Mounjaro |
| Medtronic, INC. | $104.35 | 2025 | Inceptiv |
| Biohaven Pharmaceuticals, INC. | $92.33 | 2021 | |
| Abbvie INC. | $49.37 | 2022-2025 | |
| Exact Sciences Corporation | $45.58 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.44 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $40.35 | 2023-2025 | Auvelity |
| Amgen INC. | $36.21 | 2019-2020 | |
| Corium, LLC | $34.81 | 2022-2023 | Azstarys |
| Pfizer INC. | $33.19 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.98 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.08 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.47 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $19.49 | 2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $17.20 | 2025 | Spravato |
| Daiichi Sankyo INC. | $17.15 | 2019 | |
| Collegium Pharmaceutical, INC. | $16.53 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.02 | 2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $14.43 | 2023 | Rexulti |
| Lundbeck LLC | $13.50 | 2025 | Rexulti |
| Shionogi INC | $12.84 | 2019 | |
| Noven Therapeutics, LLC | $12.70 | 2023 | Xelstrym, Secuado |
| Biodelivery Sciences International, INC. | $12.49 | 2019 | |
| Medtronic Vascular, INC. | $12.11 | 2019 | |
| Fidia Pharma USA INC. | $8.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miriam Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.